• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Viraj Narayanan Discusses the Impacts of Real-World Data on Clinical Research

Video

The integration of real-world data into clinical research may mark a shift away from clinical trial information, said Viraj Narayanan, MBA, vice president of Life Sciences at COTA Healthcare.

The integration of real-world data into clinical research may mark a shift away from clinical trial information, said Viraj Narayanan, MBA, vice president of Life Sciences at COTA Healthcare.

Transcript

How has a growing understanding and acceptance of real-world data led to it being used more in clinical research?

When you think about the real world data movement, in the beginning of it, it really happened 5 or 6 years ago with the Affordable Care Act, where there was EMR adoption and it was forced on providers. You see this huge spike from, basically EMR adoption in the tens to the eighties in about 5 or 6 years. All this information, which used to be in a black box, is now digitized. The second main milestone was the Affordable Care Act, which essentially mandated for the first time that the federal government would consider alternatives to traditional clinical trial information, ie, real-world data. Since then, what is really driving adoption in consideration of real-world data is validation work, cross-industry validation work. So, I think about the last year and think about the Friends of Cancer research efforts that have that have come a long way. I think about Duke Margolis, and a lot of these policy stakeholders that are working with industry partners, with data companies, and sponsors, to define what are real world data endpoints. How do we consider this information in lieu of clinical trial information? Of course, the best way to advance the movement is examples. Probably the most exciting example this year was Pfizer's Ibrance being approved with no clinical trial information at all, exclusively using real world data. So, I think what we're going to see moving forward is continued applications and adoptions like Pfizer Ibrance as well as additional methodology work.

Related Videos
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center.
Debra Boyer, MD, MHPE, ATSF.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Plasminogen is vital in the body's coagulation process and breaking down clots | image credit: peterschreiber.media - stock.adobe.com
ISPOR 2024 Recap
Chris Pagnani, MD, PC
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.